{
    "clinical_study": {
        "@rank": "20072", 
        "arm_group": [
            {
                "arm_group_label": "MG1109", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the immunogenicity and safety of the\n      investigational vaccine in the subjects during their participation in the study."
        }, 
        "brief_title": "Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adults who are available for follow-up during the study\n\n        Exclusion Criteria:\n\n          -  Subjects with history of exposure to the H5N1 subtype or H5N1 subtype vaccine\n\n          -  Subjects with immune system disorder including immune deficiency disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "420", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01987011", 
            "org_study_id": "MG1109_P3"
        }, 
        "intervention": {
            "arm_group_label": "MG1109", 
            "description": "Investigational Product : MG1109 Dose : 0.5 mL Intramuscularly injection, twice at an interval of 21 days", 
            "intervention_name": "MG1109", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Avian influenza", 
        "lastchanged_date": "April 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ansan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Korea University Ansan Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Inchon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Inha University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Korea University Guro Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suwon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Catholic University Of Korea ST. Vincent's Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Immunogenicity and Safety of 'MG1109(Egg-based, Pre-pandemic Influenza(H5N1) Vaccine)' Administered Intramuscularly in Healthy Adult Volunteers", 
        "overall_official": {
            "affiliation": "Korea University Guro Hospital", 
            "last_name": "Woo Joo Kim, MD, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety(MFDS)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of subjects achieving post-vaccination Hemagglutination Inhibition(HI) antibody titer \u2265 1:40", 
                "safety_issue": "No", 
                "time_frame": "1st vaccination ~ 21 days after 2nd vaccination"
            }, 
            {
                "measure": "Percentage of subjects achieving post-vaccination seroconversion for Hemagglutination Inhibition(HI) antibody", 
                "safety_issue": "No", 
                "time_frame": "1st vaccination ~ 21 days after 2nd vaccination"
            }, 
            {
                "measure": "GMR(Geometric Mean Ratio) of Hemagglutination Inhibition(HI) antibody titer at post-vaccination compared to pre-vaccination", 
                "safety_issue": "No", 
                "time_frame": "1st vaccination ~ 21 days after 2nd vaccination"
            }, 
            {
                "measure": "The percentage of subjects reporting solicited adverse events from the date of vaccination until 7 days after each vaccination", 
                "safety_issue": "Yes", 
                "time_frame": "Each vaccination ~ 7 days after each vaccination"
            }, 
            {
                "measure": "The percentage of subjects reporting unsolicited adverse events from the date of 1st vaccination until 24weeks after 2nd vaccination", 
                "safety_issue": "Yes", 
                "time_frame": "1st vaccination ~ 24 weeks after 2nd vaccination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01987011"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "GMT(Geometric Mean Titer) of Hemagglutination Inhibition(HI) antibody titer pre-vaccination and post-vaccination", 
                "safety_issue": "No", 
                "time_frame": "1st vaccination ~ 21 days after 2nd vaccination"
            }, 
            {
                "measure": "GMT(Geometric Mean Titer) and GMR(Geometric Mean Ratio) of neutralizing antibody titer pre-vaccination and post-vaccination", 
                "safety_issue": "No", 
                "time_frame": "1st vaccination ~ 21 days after 2nd vaccination"
            }, 
            {
                "measure": "Vital signs(body temperature, pulse)", 
                "safety_issue": "Yes", 
                "time_frame": "1st vaccination ~ 21 days after 2nd vaccination"
            }, 
            {
                "measure": "The results of physical examinations", 
                "safety_issue": "No", 
                "time_frame": "1st vaccination ~ 21 days after 2nd vaccination"
            }, 
            {
                "measure": "Lab results(Hematology, Blood chemistry, Urinalysis)", 
                "safety_issue": "No", 
                "time_frame": "1st vaccination ~ 21 days after 2nd vaccination"
            }
        ], 
        "source": "Green Cross Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Green Cross Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}